ALLERGAN PLC (NYSE:AGN) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(d)

Election of Director and Committee Appointments

On July18, 2017, the Board of Directors (the “Board”) of Allergan plc (the “Company”) appointed Mr.JosephH. Boccuzi as a director (“Director”) of the Company, effective immediately. The Board is currently comprised of 13 Directors. On July 19, 2017, Mr.Boccuzi was also appointed to serve on the Compensation Committee (the “Compensation Committee”) of the Board.

Mr.Boccuzi retired from Spencer Stuart, Inc. (“Spencer Stuart”) in December 2016 after 24 years of service, where he played a central role in establishing and building the firm’s Life Sciences Practice. He served in positions of increasing responsibility within Spencer Stuart, most recently as a Partner in Spencer Stuart’s Global Life Sciences, Board and Chief Executive Officer Practices. Prior to joining Spencer Stuart, Mr.Boccuzi worked in executive search, venture capital and corporate management roles. He served as a consultant with Paul R. Ray& Company, an executive search firm. Prior to that, he worked as a Financial Advisor for Merrill Lynch, Pierce, Fenner& Smith, Incorporated. Mr.Boccuzi also held several leadership positions at National Patent Development Corporation, a venture capital firm specializing in medical technology and investment throughout the U.S. and worldwide. While there, he managed four medical startup operations, serving as chief operating officer, board member and adviser to the board of directors of each such operation. Prior to that, Mr.Boccuzi worked in sales for Xerox Corporation.

Mr.Boccuzi will receive compensation for his service as a non-employee director of the Company’s Board in accordance with the terms of the Company’s director compensation program, which is described in the Company’s Definitive Proxy Statement on Schedule 14A filed with the SEC on March24, 2017.

In addition, on July19, 2017, Ms.AdrianeM. Brown, a current Director, was appointed to serve on the Audit and Compliance Committee of the Board.

(e)

Severance Plan for Senior Management

On July20, 2017, the Compensation Committee of the Board approved the Allergan plc 2017 Executive Severance Plan (the “Severance Plan”). The Company’s executive officers other than the Chief Executive Officer, as well as certain other key management members, in each case who are designated by the Compensation Committee from time to time (collectively, the “Participants”), will participate in the Severance Plan.

The Severance Plan provides each Participant with the following severance payments and benefits upon a termination of employment either (1)by the Company without “Cause” or by the Participant for “Good Reason”, in each case, during the period beginning sixty days prior to a “Change in Control” and ending on the second anniversary of a “Change in Control” (each such capitalized term as defined in the Severance Plan) (the “CIC Protected Period”, and such termination a “CIC Termination”) or (2)by the Company without “Cause” outside of the CIC Protected Period (a “Non-CIC Termination”):

Treatment of any outstanding bonus awards, equity awards and long-term incentive awards upon any termination of employment will be governed by the terms of the applicable plan and award agreement and not by the Severance Plan.

A Participant’s receipt of severance payments and benefits under the Severance Plan is conditioned upon his or her execution of an effective release of claims against the Company and compliance with any restrictive covenants, including non-competition, non-solicitation and other customary restrictive covenants, as set forth in such release. Payments and benefits under the Severance Plan will be offset against any duplicate payments or benefits a Participant may be entitled to under any other severance plan, agreement, arrangement or program of the Company.

Participants are not entitled to receive an excise tax gross-up. Rather, any payment or benefit received by the Participant (whether payable under the terms of the Severance Plan or any other plan or arrangement with the Company or an affiliate of the Company) that would constitute a “parachute payment” within the meaning of Internal Revenue Code Section280G will be reduced to the extent necessary so that no portion will be subject to any excise tax but only if, by reason of such reduction, the net after-tax benefit received by the Participant exceeds the net after-tax benefit that would be received by the Participant if no reduction was made.

This summary of the Severance Plan does not purport to be complete and is subject to and qualified in its entirety by reference to the text of the Severance Plan, which will be filed with the Company’s next Quarterly Report on Form 10-Q.